Virogin Announces Collaboration of Second-Generation VG201 with Akeso’s AK112 for Colorectal Cancer Liver Metastasis
April 16, 2025 Virogin Biotech, a clinical stage biotech company specializing in next-generation oncolytic viruses, today announced a landmark clinical collaboration with Akeso Inc. (9926.HK) to advance a multi‑center, open‑label Phase Ib/II study evaluating the combination of Virogin’s VG201 with Akeso’s breakthrough bispecific antibody Ivonescimab (AK112). This study targets advanced colorectal cancer liver metastasis (CRLM), […]
Virogin’s Oncolytic Virus VG161 Clinical Data Published in Nature: Ignites Hope for Advanced Liver Cancer Patients
On March 19, Nature published clinical research data by the First Affiliated Hospital of Zhejiang University on VG161, an oncolytic virus developed by Virogin Biotech. The study focused on patients with advanced hepatocellular carcinoma (HCC) who had failed multiple lines of treatment. Results demonstrated that VG161 not only exhibited excellent safety but also significantly extended […]
